^
Association details:
| Biomarker: | HES1 overexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial
Published date:
11/06/2019
Excerpt:
...131 previously untreated young (≤65 years) pts with MCL….Pts received IR induction (part-A),...GEP was performed in 18 pts (2 PR, 16 CR on part A). Pts in PR had higher expression of HES1 while those in CR had significantly higher expression of CTLA4 and ITK genes compared with those in PR.
DOI:
https://doi.org/10.1182/blood-2019-126044
Trial ID:
